Fredun Pharmaceuticals Q2 Results FY27: Net Profit Jumps 96.92% to Rs 18.57 Cr, Revenue Rs 267.64 Cr, PAT Rs 18.57 Cr
- November 5, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Fredun Pharmaceuticals Q2 Results FY27 were declared on 5 November 2026 and cover the quarterly results for July to September 2026. Revenue stood at Rs 267.64 Cr, up 84.21% YoY from Rs 145.29 Cr, while net profit reached Rs 18.57 Cr against Rs 9.43 Cr, a 96.92% rise. This YoY growth in both lines is the central fact of the quarter.
Fredun Pharmaceuticals Ltd (FREDUN) Q2 Results FY27 announced on 5 November 2026, covering the company’s financial performance for the July to September quarter. The company reported revenue of Rs 267.64 Cr and PAT of Rs 18.57 Cr. The results date was 5 November 2026, and Fredun Pharmaceuticals Q2 Results FY27 compare that quarter with July to September of last year, so every figure below reads as a YoY comparison.
This results analysis of Fredun Pharmaceuticals Q2 Results covers the financial highlights, business drivers, outlook and risks that follow, as Univest reads the numbers. It starts with the Financial Highlights table, which sets revenue and net profit side by side for the two quarters.
Click Here – Get Free Investment Predictions
Fredun Pharmaceuticals Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 267.64 Cr | Rs 145.29 Cr | +84.21% YoY |
| Net Profit (PAT) | Rs 18.57 Cr | Rs 9.43 Cr | +96.92% YoY |
Source: company filing for Fredun Pharmaceuticals Q2 Results FY27, 5 November 2026. Figures in Rs Crore.
Key Takeaways from Fredun Pharmaceuticals Q2 Results: What Stands Out
- Revenue rose 84.21% YoY to Rs 267.64 Cr from Rs 145.29 Cr in the same quarter of last year, the base for the profit line below.
- Net profit climbed 96.92% to Rs 18.57 Cr from Rs 9.43 Cr, the faster YoY growth of the two lines reported in Fredun Pharmaceuticals Q2 Results FY27.
- Revenue has risen in each of the last 4 quarters, so the latest figure of Rs 267.64 Cr extends a run of increases.
- Return on equity of 16.09% in FY26 gives the full-year context for the quarterly net profit of Rs 18.57 Cr.
- Debt at 0.84 times total assets in FY26 is the balance sheet headline, and the performance analysis next puts this quarter in context.
Fredun Pharmaceuticals Q2 Results FY27: Performance Analysis
Fredun Pharmaceuticals reported revenue of Rs 267.64 Cr for July to September 2026, up 84.21% YoY from Rs 145.29 Cr, while net profit rose 96.92% to Rs 18.57 Cr from Rs 9.43 Cr. The results analysis shows net profit growing faster than revenue over the same period.
Fredun Pharmaceuticals Q2 Results FY27 show both lines moving up together in YoY terms, since revenue added 84.21% and net profit added 96.92%. The supplied figures confirm these movements but do not establish a specific cause for the pace of either line.
For Fredun Pharmaceuticals Q2 Results, the next disclosures to track on the Univest Screener are the following quarterly results, where revenue and net profit can be compared again, which is where the results analysis turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points to three business factors, and revenue comes first. Revenue grew 84.2% year on year to Rs 267.64 Cr in the latest quarter, which forms the base for the net profit line discussed in this section.
Net Profit Rise – Net profit rose 96.9% year on year to Rs 18.57 Cr, the largest movement in Fredun Pharmaceuticals Q2 Results FY27 and the line that carries the most weight in the quarterly results.
Consecutive Revenue Growth – Revenue has risen in each of the last 4 quarters, so the latest quarter continues an established run of increases rather than standing alone as a single data point.
FY27 Outlook After Fredun Pharmaceuticals Q2 Results
FY27 full-year results will depend on the quarters still to be reported, and this results analysis therefore treats the July to September 2026 quarter as one data point in the year. The net profit of Rs 18.57 Cr and revenue of Rs 267.64 Cr form the reference for those later comparisons.
Fredun Pharmaceuticals Q2 Results FY27 also give later filings a clear YoY yardstick, alongside a return on equity of 16.09% in FY26. Each future disclosure can be read against these figures, and the risks below show which ratios deserve a closer look.
Key Risks to Watch After Fredun Pharmaceuticals Q2 Results FY27
High Debt Level
Debt is high at 0.84 times total assets in FY26. This balance sheet ratio is a full-year measure, and it sits alongside the quarterly figures without being explained by them or by the 96.92% net profit rise.
Thin Net Profit Margin
Net profit margin was thin at 6.9% in the latest quarter. Readers of Fredun Pharmaceuticals Q2 Results FY27 can track whether this share of revenue reaching net profit changes in later filings, since it shows how much profit each rupee of revenue carries.
Rising Debt-to-Assets
Debt-to-assets rose from 0.78 in FY22 to 0.84 in FY26. This longer trend sits against the quarterly YoY growth in revenue and net profit, so the two readings need to be weighed together.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Fredun Pharmaceuticals Q2 Results FY27 show revenue of Rs 267.64 Cr and net profit of Rs 18.57 Cr, both higher YoY. Return on equity stood at 16.09% in FY26, and the debt and margin ratios remain the main counterweights to the sharp net profit movement. Taken together, these quarterly results describe a quarter where revenue and net profit both rose. Anyone reading Fredun Pharmaceuticals Q2 Results should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Fredun Pharmaceuticals Q2 Results FY27
What are Fredun Pharmaceuticals Q2 Results FY27?
Ans. Fredun Pharmaceuticals Q2 Results FY27 are the quarterly results for July to September 2026, with revenue of Rs 267.64 Cr and net profit of Rs 18.57 Cr. Alongside this, the Quick Answer summarises the key YoY movements.
What is the results date for Fredun Pharmaceuticals Q2 Results FY27?
Ans. The results date for Fredun Pharmaceuticals Q2 Results FY27 was 5 November 2026, when Fredun Pharmaceuticals declared its quarterly results. This results date also anchors the opening paragraphs, which describe the July to September 2026 quarter.
What revenue was reported in Fredun Pharmaceuticals Q2 Results FY27?
Ans. Fredun Pharmaceuticals reported revenue of Rs 267.64 Cr in the quarter, compared with Rs 145.29 Cr a year earlier. This 84.21% YoY growth is shown in the Financial Highlights table near the top.
What net profit was reported in Fredun Pharmaceuticals Q2 Results FY27?
Ans. Net profit was Rs 18.57 Cr against Rs 9.43 Cr in the same quarter last year, which means a 96.92% rise. The Key Takeaways section lists this as the faster of the two lines.
How much YoY growth did revenue show in Fredun Pharmaceuticals Q2 Results FY27?
Ans. Revenue showed YoY growth of 84.21%, rising from Rs 145.29 Cr to Rs 267.64 Cr, while net profit grew faster. The Performance Analysis section sets the two lines side by side for comparison.
Did net profit rise or fall in Fredun Pharmaceuticals Q2 Results?
Ans. Fredun Pharmaceuticals Q2 Results show net profit rising 96.92% YoY to Rs 18.57 Cr, so the direction is clearly up. The Performance Analysis explains how this compares with the 84.21% rise in revenue.
What was the revenue trend in Fredun Pharmaceuticals Q2 Results FY27?
Ans. Revenue has risen in each of the last 4 quarters, with the latest at Rs 267.64 Cr, which means the YoY growth extends a run of increases. This trend is covered in the Key Business Factors section.
What was the net profit margin in Fredun Pharmaceuticals Q2 Results FY27?
Ans. Net profit margin was thin at 6.9% in the latest quarter, which means a small share of each rupee of revenue reached net profit. This ratio is covered in the Key Risks section.
What business factors shaped Fredun Pharmaceuticals Q2 Results FY27?
Ans. Three factors shaped the quarter: revenue growth of 84.2%, a 96.9% rise in net profit and four straight quarters of rising revenue, with return on equity at 16.09%. The Key Business Factors section covers them.
What are the key risks after Fredun Pharmaceuticals Q2 Results FY27?
Ans. The listed risks are debt at 0.84 times total assets in FY26, a thin net profit margin of 6.9% and debt-to-assets rising from 0.78 in FY22. The Key Risks section explains each of them.
What is the outlook after Fredun Pharmaceuticals Q2 Results?
Ans. FY27 full-year results will depend on the quarters still to be reported, so this quarter is one data point. Alongside this, the Outlook section treats revenue of Rs 267.64 Cr as the reference for later comparisons.
Where can I find the complete Fredun Pharmaceuticals Q2 Results FY27 data?
Ans. The complete data sits in the Financial Highlights table, drawn from the filing dated 5 November 2026, while the Univest Screener and Univest app let readers revisit the quarterly results later.
